Philip Z. Brohawn

Trial of Anifrolumab in Active Systemic Lupus Erythematosus

Eric F. Morand, Richard Furie, Yoshiya Tanaka et al. · New England Journal of Medicine · 2019 · 1.3K citations · Full text

Life Sciences, Immunology, Pharmacotherapy +9

Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus

Richard Furie, Munther A. Khamashta, Joan T. Merrill et al. · Arthritis & Rheumatology · 2016 · 867 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial

Richard Furie, Eric F. Morand, Ian N Bruce et al. · The Lancet Rheumatology · 2019 · 482 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +14

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

Suzanne I.S. Mosely, John E. Prime, Richard C.A. Sainson et al. · Cancer Immunology Research · 2016 · 423 citations

Medicine, Immunology, Oncology +16

Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway

Brandon W. Higgs, Zheng Liu, Barbara White et al. · Annals of the Rheumatic Diseases · 2011 · 408 citations

Life Sciences, Immunology, Molecular Medicine +17